Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Fennec Pharmaceuticals (FENC) Non-Current Receivables (2025)

Fennec Pharmaceuticals filings provide 1 years of Non-Current Receivables readings, the most recent being $2.8 million for Q4 2025.

  • On a quarterly basis, Non-Current Receivables changed N/A to $2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a N/A change, with the full-year FY2025 number at $2.8 million, changed N/A from a year prior.
  • Non-Current Receivables hit $2.8 million in Q4 2025 for Fennec Pharmaceuticals, up from $2.5 million in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $3.3 million in Q2 2025 to a low of $2.5 million in Q3 2025.